Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 May 15;99(10):2438–2445. doi: 10.1172/JCI119427

Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo.

P C Rensen 1, M Oosten 1, E Bilt 1, M Eck 1, J Kuiper 1, T J Berkel 1
PMCID: PMC508084  PMID: 9153287

Abstract

Chylomicrons have been shown to protect mice and rats against a lethal dose of lipopolysaccharide and may serve as a therapeutic means to protect against endotoxemia. However, the requisite of isolation from human lymph hampers pharmaceutical application. Recently, we developed recombinant chylomicrons from commercially available lipids and human recombinant apolipoprotein E. The current study explored the effectiveness of these apoE-enriched emulsions in redirecting LPS from Kupffer cells to liver parenchymal cells. Upon injection into rats, 125I-LPS rapidly and specifically associated with the liver (64.3+/-3.1% of the injected dose) and spleen (4.1+/-0.7%). The uptake of LPS by the spleen was four- to fivefold reduced upon incubation with the apoE-enriched emulsion or free apoE (P < 0.0001), but not with emulsion alone or Lipofundin. Within the liver, 125I-LPS mainly associated with Kupffer cells. The uptake by Kupffer cells was eight- to ninefold reduced by the apoE-enriched emulsion or apoE alone (P < 0.01), and a 19.6-fold increased uptake ratio by liver parenchymal cells over Kupffer cells was observed. The emulsion without apoE had no effect on the in vivo kinetics of LPS. LPS interacted selectively with the apoE moiety of the recombinant chylomicron. Emulsion-associated and free apoE bound approximately two molecules of LPS, possibly by its exposed hydrophilic domain involving arginine residues. We anticipate that the protecting effect of endogenous chylomicrons against LPS-induced endotoxemia may result from the apoE moiety and that human recombinant apoE may serve as a therapeuticum to protect against endotoxemia.

Full Text

The Full Text of this article is available as a PDF (244.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelmelk B. J., An Y. Q., Geerts M., Thijs B. G., de Boer H. A., MacLaren D. M., de Graaff J., Nuijens J. H. Lactoferrin is a lipid A-binding protein. Infect Immun. 1994 Jun;62(6):2628–2632. doi: 10.1128/iai.62.6.2628-2632.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  3. Bijsterbosch M. K., Ziere G. J., Van Berkel T. J. Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells. Mol Pharmacol. 1989 Sep;36(3):484–489. [PubMed] [Google Scholar]
  4. Blouin A., Bolender R. P., Weibel E. R. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J Cell Biol. 1977 Feb;72(2):441–455. doi: 10.1083/jcb.72.2.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chensue S. W., Terebuh P. D., Remick D. G., Scales W. E., Kunkel S. L. In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. Am J Pathol. 1991 Feb;138(2):395–402. [PMC free article] [PubMed] [Google Scholar]
  6. Cohen M. S., Mao J., Rasmussen G. T., Serody J. S., Britigan B. E. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J Infect Dis. 1992 Dec;166(6):1375–1378. doi: 10.1093/infdis/166.6.1375. [DOI] [PubMed] [Google Scholar]
  7. Elass-Rochard E., Roseanu A., Legrand D., Trif M., Salmon V., Motas C., Montreuil J., Spik G. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem J. 1995 Dec 15;312(Pt 3):839–845. doi: 10.1042/bj3120839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Emancipator K., Csako G., Elin R. J. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun. 1992 Feb;60(2):596–601. doi: 10.1128/iai.60.2.596-601.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Feingold K. R., Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest. 1987 Jul;80(1):184–190. doi: 10.1172/JCI113046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Feingold K. R., Staprans I., Memon R. A., Moser A. H., Shigenaga J. K., Doerrler W., Dinarello C. A., Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res. 1992 Dec;33(12):1765–1776. [PubMed] [Google Scholar]
  11. Flegel W. A., Baumstark M. W., Weinstock C., Berg A., Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun. 1993 Dec;61(12):5140–5146. doi: 10.1128/iai.61.12.5140-5146.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Freudenberg M. A., Freudenberg N., Galanos C. Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats. Br J Exp Pathol. 1982 Feb;63(1):56–65. [PMC free article] [PubMed] [Google Scholar]
  13. Harris H. W., Grunfeld C., Feingold K. R., Rapp J. H. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990 Sep;86(3):696–702. doi: 10.1172/JCI114765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Harris H. W., Grunfeld C., Feingold K. R., Read T. E., Kane J. P., Jones A. L., Eichbaum E. B., Bland G. F., Rapp J. H. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest. 1993 Mar;91(3):1028–1034. doi: 10.1172/JCI116259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Huettinger M., Retzek H., Eder M., Goldenberg H. Characteristics of chylomicron remnant uptake into rat liver. Clin Biochem. 1988 Apr;21(2):87–92. doi: 10.1016/s0009-9120(88)80093-6. [DOI] [PubMed] [Google Scholar]
  16. Karkhanis Y. D., Zeltner J. Y., Jackson J. J., Carlo D. J. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal Biochem. 1978 Apr;85(2):595–601. doi: 10.1016/0003-2697(78)90260-9. [DOI] [PubMed] [Google Scholar]
  17. Kaufmann R. L., Matson C. F., Beisel W. R. Hypertriglyceridemia produced by endotoxin: role of impaired triglyceride disposal mechanisms. J Infect Dis. 1976 May;133(5):548–555. doi: 10.1093/infdis/133.5.548. [DOI] [PubMed] [Google Scholar]
  18. Kawakami M., Pekala P. H., Lane M. D., Cerami A. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A. 1982 Feb;79(3):912–916. doi: 10.1073/pnas.79.3.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Levine D. M., Parker T. S., Donnelly T. M., Walsh A., Rubin A. L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12040–12044. doi: 10.1073/pnas.90.24.12040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Machnicki M., Zimecki M., Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol. 1993 Oct;74(5):433–439. [PMC free article] [PubMed] [Google Scholar]
  21. Mathison J. C., Ulevitch R. J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol. 1979 Nov;123(5):2133–2143. [PubMed] [Google Scholar]
  22. Miyazawa K., Mantel C., Lu L., Morrison D. C., Broxmeyer H. E. Lactoferrin-lipopolysaccharide interactions. Effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J Immunol. 1991 Jan 15;146(2):723–729. [PubMed] [Google Scholar]
  23. Morrison D. C., Jacobs D. M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry. 1976 Oct;13(10):813–818. doi: 10.1016/0019-2791(76)90181-6. [DOI] [PubMed] [Google Scholar]
  24. Munford R. S., Hall C. L., Dietschy J. M. Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins. Infect Immun. 1981 Dec;34(3):835–843. doi: 10.1128/iai.34.3.835-843.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nagelkerke J. F., Barto K. P., van Berkel T. J. In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cells. J Biol Chem. 1983 Oct 25;258(20):12221–12227. [PubMed] [Google Scholar]
  26. Park C. T., Wright S. D. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J Biol Chem. 1996 Jul 26;271(30):18054–18060. doi: 10.1074/jbc.271.30.18054. [DOI] [PubMed] [Google Scholar]
  27. Parker T. S., Levine D. M., Chang J. C., Laxer J., Coffin C. C., Rubin A. L. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun. 1995 Jan;63(1):253–258. doi: 10.1128/iai.63.1.253-258.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Parrillo J. E. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993 May 20;328(20):1471–1477. doi: 10.1056/NEJM199305203282008. [DOI] [PubMed] [Google Scholar]
  29. Patthy L., Smith E. L. Reversible modification of arginine residues. Application to sequence studies by restriction of tryptic hydrolysis to lysine residues. J Biol Chem. 1975 Jan 25;250(2):557–564. [PubMed] [Google Scholar]
  30. Praaning-van Dalen D. P., Brouwer A., Knook D. L. Clearance capacity of rat liver Kupffer, Endothelial, and parenchymal cells. Gastroenterology. 1981 Dec;81(6):1036–1044. [PubMed] [Google Scholar]
  31. Read T. E., Harris H. W., Grunfeld C., Feingold K. R., Calhoun M. C., Kane J. P., Rapp J. H. Chylomicrons enhance endotoxin excretion in bile. Infect Immun. 1993 Aug;61(8):3496–3502. doi: 10.1128/iai.61.8.3496-3502.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Redgrave T. G., Maranhao R. C. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta. 1985 Jun 14;835(1):104–112. doi: 10.1016/0005-2760(85)90036-0. [DOI] [PubMed] [Google Scholar]
  33. Rensen P. C., van Berkel T. J. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem. 1996 Jun 21;271(25):14791–14799. doi: 10.1074/jbc.271.25.14791. [DOI] [PubMed] [Google Scholar]
  34. Rensen P. C., van Dijk M. C., Havenaar E. C., Bijsterbosch M. K., Kruijt J. K., van Berkel T. J. Selective liver targeting of antivirals by recombinant chylomicrons--a new therapeutic approach to hepatitis B. Nat Med. 1995 Mar;1(3):221–225. doi: 10.1038/nm0395-221. [DOI] [PubMed] [Google Scholar]
  35. Rietschel E. T., Gottert H., Lüderitz O., Westphal O. Nature and linkages of the fatty acids present in the lipid-A component of Salmonella lipopolysaccharides. Eur J Biochem. 1972 Jul 13;28(2):166–173. doi: 10.1111/j.1432-1033.1972.tb01899.x. [DOI] [PubMed] [Google Scholar]
  36. Ruiter D. J., van der Meulen J., Brouwer A., Hummel M. J., Mauw B. J., van der Ploeg J. C., Wisse E. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest. 1981 Jul;45(1):38–45. [PubMed] [Google Scholar]
  37. Ulevitch R. J., Johnston A. R., Weinstein D. B. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest. 1979 Nov;64(5):1516–1524. doi: 10.1172/JCI109610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ulevitch R. J. The preparation and characterization of a radioiodinated bacterial lipopolysaccharide. Immunochemistry. 1978 Mar;15(3):157–164. doi: 10.1016/0161-5890(78)90144-x. [DOI] [PubMed] [Google Scholar]
  39. Ulevitch R. J., Tobias P. S. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol. 1994 Feb;6(1):125–130. doi: 10.1016/0952-7915(94)90043-4. [DOI] [PubMed] [Google Scholar]
  40. Van Lenten B. J., Fogelman A. M., Haberland M. E., Edwards P. A. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2704–2708. doi: 10.1073/pnas.83.8.2704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Van Tol A., Van Gent T., Van 't Hooft F. M., Vlaspolder F. High density lipoprotein catabolism before and after partial hepatectomy. Atherosclerosis. 1978 Apr;29(4):439–448. doi: 10.1016/0021-9150(78)90172-7. [DOI] [PubMed] [Google Scholar]
  42. Vogel T., Weisgraber K. H., Zeevi M. I., Ben-Artzi H., Levanon A. Z., Rall S. C., Jr, Innerarity T. L., Hui D. Y., Taylor J. M., Kanner D. Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8696–8700. doi: 10.1073/pnas.82.24.8696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989 Jan 1;169(1):333–338. doi: 10.1084/jem.169.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wolfe R. R., Shaw J. H., Durkot M. J. Effect of sepsis on VLDL kinetics: responses in basal state and during glucose infusion. Am J Physiol. 1985 Jun;248(6 Pt 1):E732–E740. doi: 10.1152/ajpendo.1985.248.6.E732. [DOI] [PubMed] [Google Scholar]
  45. Wright S. D., Ramos R. A., Tobias P. S., Ulevitch R. J., Mathison J. C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990 Sep 21;249(4975):1431–1433. doi: 10.1126/science.1698311. [DOI] [PubMed] [Google Scholar]
  46. Wurfel M. M., Kunitake S. T., Lichenstein H., Kane J. P., Wright S. D. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994 Sep 1;180(3):1025–1035. doi: 10.1084/jem.180.3.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. van Berkel T. J., Dekker C. J., Kruijt J. K., van Eijk H. G. The interaction in vivo of transferrin and asialotransferrin with liver cells. Biochem J. 1987 May 1;243(3):715–722. doi: 10.1042/bj2430715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. van der Poll T., Braxton C. C., Coyle S. M., Boermeester M. A., Wang J. C., Jansen P. M., Montegut W. J., Calvano S. E., Hack C. E., Lowry S. F. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun. 1995 Sep;63(9):3396–3400. doi: 10.1128/iai.63.9.3396-3400.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES